creatine has been researched along with Idiopathic Parkinson Disease in 79 studies
Excerpt | Relevance | Reference |
---|---|---|
"To determine whether creatine monohydrate was more effective than placebo in slowing long-term clinical decline in participants with Parkinson disease." | 9.20 | Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. ( Aminoff, MJ; Augustine, AH; Augustine, EU; Babcock, D; Bodis-Wollner, IG; Boyd, J; Cambi, F; Chou, K; Christine, CW; Cines, M; Dahodwala, N; Derwent, L; Dewey, RB; Elm, JJ; Hauser, R; Hawthorne, K; Houghton, DJ; Kamp, C; Kieburtz, K; Leehey, M; Lew, MF; Liang, GS; Luo, ST; Mari, Z; Morgan, JC; Parashos, S; Pérez, A; Petrovitch, H; Rajan, S; Reichwein, S; Ross, GW; Roth, JT; Schneider, JS; Shannon, KM; Simon, DK; Simuni, T; Singer, C; Sudarsky, L; Tanner, CM; Tilley, BC; Umeh, CC; Williams, K; Wills, AM, 2015) |
"Both creatine and minocycline should be considered for definitive Phase III trials to determine if they alter the long term progression of Parkinson disease (PD)." | 9.12 | A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. ( , 2006) |
" Weight gain is the most common side effect of Cr, but sporadic reports about the impairment of renal function cause the most concerns with regard to its long-term use." | 6.73 | Long-term creatine supplementation is safe in aged patients with Parkinson disease. ( Bender, A; Elstner, M; Klopstock, T; Samtleben, W, 2008) |
"Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD." | 6.72 | Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. ( Bender, A; Bender, J; Elstner, M; Gasser, T; Gekeler, F; Klopstock, T; Koch, W; Moeschl, M; Müller-Myhsok, B; Schombacher, Y; Tatsch, K, 2006) |
"To determine whether creatine monohydrate was more effective than placebo in slowing long-term clinical decline in participants with Parkinson disease." | 5.20 | Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. ( Aminoff, MJ; Augustine, AH; Augustine, EU; Babcock, D; Bodis-Wollner, IG; Boyd, J; Cambi, F; Chou, K; Christine, CW; Cines, M; Dahodwala, N; Derwent, L; Dewey, RB; Elm, JJ; Hauser, R; Hawthorne, K; Houghton, DJ; Kamp, C; Kieburtz, K; Leehey, M; Lew, MF; Liang, GS; Luo, ST; Mari, Z; Morgan, JC; Parashos, S; Pérez, A; Petrovitch, H; Rajan, S; Reichwein, S; Ross, GW; Roth, JT; Schneider, JS; Shannon, KM; Simon, DK; Simuni, T; Singer, C; Sudarsky, L; Tanner, CM; Tilley, BC; Umeh, CC; Williams, K; Wills, AM, 2015) |
"Both creatine and minocycline should be considered for definitive Phase III trials to determine if they alter the long term progression of Parkinson disease (PD)." | 5.12 | A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. ( , 2006) |
"We found lower GABA+/creatine in PD with visual hallucinations (0." | 3.88 | Reduced occipital GABA in Parkinson disease with visual hallucinations. ( Allan, CL; Blamire, AM; Collerton, D; Firbank, MJ; Killen, A; Murphy, N; Parikh, J; Taylor, JP, 2018) |
"This retrospective study aimed to examine the relationship between the ratio of N-acetyl aspartate (NAA) to creatine in the substantia nigra (SN) and globus pallidus (GP) and the Hoehn-Yahr stage and Unified Parkinson Disease Rating Scale (UPDRS) score determined for patients with Parkinson disease (PD)." | 3.83 | Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease. ( Chen, J; Huang, MH; Liu, Y; Shen, YJ; Wu, G; Xing, Z, 2016) |
"Weight loss is a common symptom of Parkinson's disease and is associated with impaired quality of life." | 2.84 | Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort. ( Boyd, J; Li, R; Pérez, A; Ren, X; Wills, AM, 2017) |
" Weight gain is the most common side effect of Cr, but sporadic reports about the impairment of renal function cause the most concerns with regard to its long-term use." | 2.73 | Long-term creatine supplementation is safe in aged patients with Parkinson disease. ( Bender, A; Elstner, M; Klopstock, T; Samtleben, W, 2008) |
"Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD." | 2.72 | Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. ( Bender, A; Bender, J; Elstner, M; Gasser, T; Gekeler, F; Klopstock, T; Koch, W; Moeschl, M; Müller-Myhsok, B; Schombacher, Y; Tatsch, K, 2006) |
"Twenty-five patients with idiopathic Parkinson disease with unilateral symptoms (IPDUS) and 25 healthy volunteers were enrolled in this study." | 2.71 | MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms. ( Liu, Y; Ruan, LX; Shang, DS; Yuan, M; Zhang, LJ; Zheng, XN; Zhu, XC, 2004) |
"Creatine has no observed benefit in PD patients, although more correlated studies are still needed." | 2.55 | The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials. ( Cui, LL; Liu, LY; Liu, Z; Mo, JJ; Peng, WB; Rao, J, 2017) |
"Creatine was selected by the National Institute of Neurological Disorders and Stroke as a possible disease modifying agent for Parkinson's disease." | 2.55 | Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease. ( Ahmed, H; Awad, K; El-Jaafary, S; Elnenny, M; Gadelkarim, M; Ghanem, E; Morsi, M; Negida, A, 2017) |
"Parkinson's disease is one of the most common neurodegenerative disorders and mitochondrial dysfunction plays an important role in its pathogenesis." | 2.50 | Creatine for Parkinson's disease. ( Luo, H; Luo, M; Wang, J; Xiao, Y, 2014) |
"Pathological hallmarks of Parkinson's disease are destruction of dopaminergic neurons in the basal ganglia, especially the substantia nigra, and the presence of Lewy bodies within nerve cells." | 2.46 | Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. ( Kones, R, 2010) |
"Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD." | 2.42 | Bioenergetic approaches for neuroprotection in Parkinson's disease. ( Beal, MF, 2003) |
"The pathogenesis of Parkinson's disease (PD) remains obscure, but there is increasing evidence that impairment of mitochondrial function, oxidative damage, and inflammation are contributing factors." | 2.42 | Mitochondria, oxidative damage, and inflammation in Parkinson's disease. ( Beal, MF, 2003) |
"There are several reports of MRS in Parkinson's disease(PD) and multiple system atrophy(MSA)." | 2.40 | [Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy]. ( Aotsuka, A; Hattori, T; Shinotoh, H, 1997) |
"Curcumin (CUR) has been reported to provide neuroprotective effects on neurological disorders and modulate the gut flora in intestinal-related diseases." | 1.72 | Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease. ( Cui, C; Han, Y; Li, G; Li, H; Yu, H; Zhang, B, 2022) |
"Diagnosis of Parkinson's disease (PD) cognitive impairment at early stages is challenging compared to the stage of PD dementia where functional impairment is apparent and easily diagnosed." | 1.62 | Frontal lobe metabolic alterations characterizing Parkinson's disease cognitive impairment. ( Chaudhary, S; Goyal, V; Jagannathan, NR; Kalaivani, M; Kaloiya, GS; Kumaran, SS; Mehta, N; Sagar, R; Srivastava, AK, 2021) |
"Parkinson's disease is characterized by bradykinesia, rigidity, and tremor." | 1.56 | GABAergic changes in the thalamocortical circuit in Parkinson's disease. ( Cools, R; den Ouden, HEM; Dirkx, MFM; Helmich, RC; Scheenen, TWJ; Toni, I; van Asten, JJA; van Nuland, AJM; Zach, H, 2020) |
"21 patients with Parkinson's disease and 24 controls were examined using magnetic resonance spectroscopic imaging at 3 Tesla." | 1.40 | Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. ( Gröger, A; Klose, U; Kolb, R; Schäfer, R, 2014) |
"Patients with advanced Parkinson's disease (PD) commonly suffer with significant executive dysfunction and concomitant visual hallucinations." | 1.38 | Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. ( Duffy, S; Halliday, G; Lewis, SJ; Naismith, SL; Shine, JM, 2012) |
"Nine patients with Parkinson's disease and eight age- and gender-matched healthy controls were included in this study." | 1.37 | Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. ( Berg, D; Chadzynski, G; Godau, J; Gröger, A; Klose, U, 2011) |
"Although motor symptoms of Parkinson's disease (PD) are initially responsive to dopamine replacement therapy, nonresponsive features develop over time, suggesting that impaired dopaminergic function alone may not be wholly responsible for all the motor features of the disease." | 1.35 | Intact presupplementary motor area function in early, untreated Parkinson's disease. ( Camicioli, RM; Gee, M; Hanstock, CC; Martin, WR; Wieler, M, 2008) |
"Loss of nigral dopamine neurons in Parkinson's disease induces abnormal activation of glutamate systems in the basal ganglia." | 1.34 | Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. ( Durif, F; Fraix, V; Kickler, N; Krack, P; Krainik, A; Lamalle, L; Lebas, JF; Pollak, P; Rémy, C; Segebarth, C, 2007) |
"Although no difference was found between groups with RBD and IPD without dream enactment behavior in demographic characteristics, duration of disease, mean levodopa dosage and duration of levodopa use, all UPDRS scores (total, motor and cognitive) were worse in RBD group (p<0." | 1.33 | Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior. ( Dincer, A; Hanoglu, L; Meral, H; Ozer, F, 2006) |
"The basis for cognitive deficits in Parkinson's disease (PD) is unknown." | 1.32 | Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. ( Bastos, AC; Camicioli, RM; Emery, DJ; Fisher, NJ; Foster, SL; Hanstock, CC; Korzan, JR, 2004) |
"Six patients with idiopathic Parkinson's disease (IPD), six with clinically probable multiple system atrophy and six control subjects underwent quantitative proton magnetic resonance spectroscopy (MRS)." | 1.31 | Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. ( Clarke, CE; Lowry, M, 2000) |
"The study included 12 patients with progressive supranuclear palsy, 10 with Parkinson's disease, nine with corticobasal degeneration and 11 age-matched normal control subjects." | 1.30 | Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. ( Bertolino, A; Bonavita, S; Hallett, M; Litvan, I; Lundbom, N; Patronas, NJ; Tedeschi, G, 1997) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (5.06) | 18.7374 |
1990's | 12 (15.19) | 18.2507 |
2000's | 27 (34.18) | 29.6817 |
2010's | 30 (37.97) | 24.3611 |
2020's | 6 (7.59) | 2.80 |
Authors | Studies |
---|---|
Donahue, EK | 1 |
Bui, V | 1 |
Foreman, RP | 1 |
Duran, JJ | 1 |
Venkadesh, S | 1 |
Choupan, J | 1 |
Van Horn, JD | 1 |
Alger, JR | 1 |
Jakowec, MW | 1 |
Petzinger, GM | 1 |
O'Neill, J | 1 |
Cengiz, S | 1 |
Arslan, DB | 1 |
Kicik, A | 1 |
Erdogdu, E | 1 |
Yildirim, M | 1 |
Hatay, GH | 1 |
Tufekcioglu, Z | 1 |
Uluğ, AM | 1 |
Bilgic, B | 1 |
Hanagasi, H | 1 |
Demiralp, T | 1 |
Gurvit, H | 1 |
Ozturk-Isik, E | 1 |
Cui, C | 1 |
Han, Y | 1 |
Li, H | 1 |
Yu, H | 1 |
Zhang, B | 1 |
Li, G | 1 |
Yuan, M | 2 |
Du, N | 1 |
Song, Z | 1 |
van Nuland, AJM | 1 |
den Ouden, HEM | 1 |
Zach, H | 1 |
Dirkx, MFM | 1 |
van Asten, JJA | 1 |
Scheenen, TWJ | 1 |
Toni, I | 1 |
Cools, R | 1 |
Helmich, RC | 1 |
Chaudhary, S | 1 |
Kumaran, SS | 1 |
Goyal, V | 1 |
Kalaivani, M | 1 |
Kaloiya, GS | 1 |
Sagar, R | 1 |
Mehta, N | 1 |
Srivastava, AK | 1 |
Jagannathan, NR | 1 |
Simon, DK | 2 |
Wu, C | 1 |
Tilley, BC | 5 |
Lohmann, K | 1 |
Klein, C | 1 |
Payami, H | 1 |
Wills, AM | 4 |
Aminoff, MJ | 3 |
Bainbridge, J | 2 |
Dewey, R | 1 |
Hauser, RA | 2 |
Schaake, S | 1 |
Schneider, JS | 2 |
Sharma, S | 1 |
Singer, C | 2 |
Tanner, CM | 2 |
Truong, D | 1 |
Wei, P | 1 |
Wong, PS | 1 |
Yang, T | 1 |
Mo, JJ | 1 |
Liu, LY | 1 |
Peng, WB | 1 |
Rao, J | 1 |
Liu, Z | 1 |
Cui, LL | 1 |
Li, R | 1 |
Pérez, A | 3 |
Ren, X | 1 |
Boyd, J | 2 |
Barbagallo, G | 1 |
Arabia, G | 1 |
Morelli, M | 1 |
Nisticò, R | 1 |
Novellino, F | 1 |
Salsone, M | 1 |
Rocca, F | 1 |
Quattrone, A | 2 |
Caracciolo, M | 1 |
Sabatini, U | 1 |
Cherubini, A | 1 |
Firbank, MJ | 1 |
Parikh, J | 1 |
Murphy, N | 1 |
Killen, A | 1 |
Allan, CL | 1 |
Collerton, D | 1 |
Blamire, AM | 1 |
Taylor, JP | 1 |
Zhou, B | 1 |
Yuan, F | 1 |
He, Z | 1 |
Tan, C | 1 |
Gröger, A | 2 |
Kolb, R | 1 |
Schäfer, R | 1 |
Klose, U | 2 |
Xiao, Y | 1 |
Luo, M | 1 |
Luo, H | 1 |
Wang, J | 2 |
Chagas, MH | 1 |
Zuardi, AW | 1 |
Tumas, V | 1 |
Pena-Pereira, MA | 1 |
Sobreira, ET | 1 |
Bergamaschi, MM | 1 |
dos Santos, AC | 1 |
Teixeira, AL | 1 |
Hallak, JE | 1 |
Crippa, JA | 1 |
Ciurleo, R | 2 |
Di Lorenzo, G | 2 |
Bramanti, P | 2 |
Marino, S | 2 |
Kieburtz, K | 1 |
Elm, JJ | 5 |
Babcock, D | 1 |
Hauser, R | 1 |
Ross, GW | 2 |
Augustine, AH | 1 |
Augustine, EU | 1 |
Bodis-Wollner, IG | 1 |
Cambi, F | 2 |
Chou, K | 1 |
Christine, CW | 1 |
Cines, M | 1 |
Dahodwala, N | 1 |
Derwent, L | 1 |
Dewey, RB | 1 |
Hawthorne, K | 1 |
Houghton, DJ | 1 |
Kamp, C | 1 |
Leehey, M | 1 |
Lew, MF | 1 |
Liang, GS | 2 |
Luo, ST | 1 |
Mari, Z | 1 |
Morgan, JC | 1 |
Parashos, S | 1 |
Petrovitch, H | 1 |
Rajan, S | 1 |
Reichwein, S | 1 |
Roth, JT | 1 |
Shannon, KM | 1 |
Simuni, T | 1 |
Sudarsky, L | 1 |
Umeh, CC | 2 |
Williams, K | 1 |
Li, Z | 1 |
Wang, P | 1 |
Yu, Z | 1 |
Cong, Y | 1 |
Sun, H | 1 |
Zhang, J | 2 |
Sun, C | 1 |
Zhang, Y | 1 |
Ju, X | 1 |
Bonanno, L | 1 |
Luo, S | 2 |
Augustine, EF | 2 |
Dhall, R | 1 |
Videnovic, A | 1 |
Zweig, RM | 1 |
Shulman, LM | 2 |
Nance, MA | 1 |
Suchowersky, O | 1 |
Öz, G | 1 |
Seraji-Bozorgzad, N | 1 |
Bao, F | 1 |
George, E | 1 |
Krstevska, S | 1 |
Gorden, V | 1 |
Chorostecki, J | 1 |
Santiago, C | 1 |
Zak, I | 1 |
Caon, C | 1 |
Khan, O | 1 |
Almuqbel, M | 1 |
Melzer, TR | 1 |
Myall, DJ | 1 |
MacAskill, MR | 1 |
Pitcher, TL | 1 |
Livingston, L | 1 |
Wood, KL | 1 |
Keenan, RJ | 1 |
Dalrymple-Alford, JC | 1 |
Anderson, TJ | 1 |
Wu, G | 1 |
Shen, YJ | 1 |
Huang, MH | 1 |
Xing, Z | 1 |
Liu, Y | 2 |
Chen, J | 1 |
Dorsey, ER | 1 |
Kieburtz, KK | 1 |
Drew, L | 1 |
Ahmed, H | 1 |
Gadelkarim, M | 1 |
Morsi, M | 1 |
Awad, K | 1 |
Elnenny, M | 1 |
Ghanem, E | 1 |
El-Jaafary, S | 1 |
Negida, A | 1 |
Martin, WR | 1 |
Wieler, M | 1 |
Gee, M | 1 |
Hanstock, CC | 2 |
Camicioli, RM | 2 |
Griffith, HR | 1 |
den Hollander, JA | 1 |
Okonkwo, OC | 1 |
O'Brien, T | 1 |
Watts, RL | 1 |
Marson, DC | 1 |
Bender, A | 2 |
Samtleben, W | 1 |
Elstner, M | 2 |
Klopstock, T | 2 |
Rákóczi, K | 1 |
Klivényi, P | 1 |
Vécsei, L | 1 |
Yang, L | 1 |
Calingasan, NY | 1 |
Wille, EJ | 1 |
Cormier, K | 1 |
Smith, K | 1 |
Ferrante, RJ | 1 |
Beal, MF | 4 |
Parashos, SA | 1 |
Swearingen, CJ | 1 |
Biglan, KM | 1 |
Bodis-Wollner, I | 1 |
Kones, R | 1 |
Williams, R | 1 |
Modrego, PJ | 1 |
Fayed, N | 1 |
Artal, J | 1 |
Olmos, S | 1 |
Chadzynski, G | 1 |
Godau, J | 1 |
Berg, D | 2 |
Brockmann, K | 1 |
Hilker, R | 1 |
Pilatus, U | 1 |
Baudrexel, S | 1 |
Srulijes, K | 1 |
Magerkurth, J | 1 |
Hauser, AK | 1 |
Schulte, C | 1 |
Csoti, I | 1 |
Merten, CD | 1 |
Gasser, T | 2 |
Hattingen, E | 1 |
Lewis, SJ | 1 |
Shine, JM | 1 |
Duffy, S | 1 |
Halliday, G | 1 |
Naismith, SL | 1 |
Lawson, AB | 1 |
He, B | 1 |
Axelson, D | 1 |
Bakken, IJ | 1 |
Susann Gribbestad, I | 1 |
Ehrnholm, B | 1 |
Nilsen, G | 1 |
Aasly, J | 1 |
Rottenberg, DA | 1 |
Baik, HM | 1 |
Choe, BY | 2 |
Son, BC | 2 |
Jeun, SS | 1 |
Kim, MC | 2 |
Lee, KS | 2 |
Kim, BS | 2 |
Lee, JM | 1 |
Lee, HK | 2 |
Suh, TS | 2 |
Zheng, XN | 1 |
Zhu, XC | 1 |
Ruan, LX | 1 |
Zhang, LJ | 1 |
Shang, DS | 1 |
Korzan, JR | 1 |
Foster, SL | 1 |
Fisher, NJ | 1 |
Emery, DJ | 1 |
Bastos, AC | 1 |
Watanabe, H | 1 |
Fukatsu, H | 1 |
Katsuno, M | 1 |
Sugiura, M | 1 |
Hamada, K | 1 |
Okada, Y | 1 |
Hirayama, M | 1 |
Ishigaki, T | 1 |
Sobue, G | 1 |
Brosnan, JT | 1 |
Jacobs, RL | 1 |
Stead, LM | 1 |
Brosnan, ME | 1 |
LeWitt, PA | 1 |
Hanoglu, L | 1 |
Ozer, F | 1 |
Meral, H | 1 |
Dincer, A | 1 |
Koch, W | 1 |
Schombacher, Y | 1 |
Bender, J | 1 |
Moeschl, M | 1 |
Gekeler, F | 1 |
Müller-Myhsok, B | 1 |
Tatsch, K | 1 |
Kickler, N | 1 |
Krack, P | 1 |
Fraix, V | 1 |
Lebas, JF | 1 |
Lamalle, L | 1 |
Durif, F | 1 |
Krainik, A | 1 |
Rémy, C | 1 |
Segebarth, C | 1 |
Pollak, P | 1 |
Couzin, J | 1 |
Bloom, MZ | 1 |
Llumiguano, C | 1 |
Kovacs, N | 1 |
Usprung, Z | 1 |
Schwarcz, A | 1 |
Dóczi, TP | 1 |
Balas, I | 1 |
Wilson, TW | 1 |
Rajput, AH | 1 |
Davie, CA | 2 |
Wenning, GK | 2 |
Barker, GJ | 2 |
Tofts, PS | 1 |
Kendall, BE | 1 |
Quinn, N | 2 |
McDonald, WI | 1 |
Marsden, CD | 1 |
Miller, DH | 2 |
Bowen, BC | 1 |
Block, RE | 1 |
Sanchez-Ramos, J | 1 |
Pattany, PM | 1 |
Lampman, DA | 1 |
Murdoch, JB | 1 |
Quencer, RM | 1 |
Brennan, A | 1 |
Shiino, A | 1 |
Matsuda, M | 1 |
Morikawa, S | 1 |
Inubushi, T | 1 |
Akiguchi, I | 1 |
Handa, J | 1 |
Aotsuka, A | 1 |
Shinotoh, H | 1 |
Hattori, T | 1 |
Federico, F | 1 |
Simone, IL | 1 |
Lucivero, V | 1 |
De Mari, M | 1 |
Giannini, P | 1 |
Iliceto, G | 1 |
Mezzapesa, DM | 1 |
Lamberti, P | 1 |
Clarke, CE | 2 |
Lowry, M | 2 |
Horsman, A | 1 |
Ellis, CM | 1 |
Lemmens, G | 1 |
Williams, SC | 1 |
Simmons, A | 1 |
Dawson, J | 1 |
Leigh, PN | 1 |
Chaudhuri, KR | 1 |
Cruz, CJ | 1 |
Meyerhoff, DJ | 1 |
Graham, SH | 1 |
Weiner, MW | 1 |
Tedeschi, G | 1 |
Litvan, I | 1 |
Bonavita, S | 1 |
Bertolino, A | 1 |
Lundbom, N | 1 |
Patronas, NJ | 1 |
Hallett, M | 1 |
Park, JW | 1 |
Shinn, KS | 1 |
Taylor-Robinson, SD | 1 |
Turjanski, N | 1 |
Bhattacharya, S | 1 |
Seery, JP | 1 |
Sargentoni, J | 1 |
Brooks, DJ | 1 |
Bryant, DJ | 1 |
Cox, IJ | 1 |
Lucetti, C | 1 |
Del Dotto, P | 1 |
Gambaccini, G | 1 |
Bernardini, S | 1 |
Bianchi, MC | 1 |
Tosetti, M | 1 |
Bonuccelli, U | 1 |
Landin, S | 1 |
Hagenfeldt, L | 1 |
Saltin, B | 1 |
Wahren, J | 1 |
Dziedzic, SW | 1 |
Dziedzic, LB | 1 |
Gitlow, SE | 1 |
Fine, W | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1)[NCT00449865] | Phase 3 | 1,741 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Futility) | ||
Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease[NCT02324426] | Phase 1 | 15 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
Phase 3 Trial of Coenzyme Q10 in Mitochondrial Disease[NCT00432744] | Phase 3 | 24 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease[NCT00909545] | Phase 2 | 99 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
All outcomes were coded such that higher scores indicated worse outcomes. Patients were ranked on each outcome and their ranks were summed (summed-ranks). Higher summed ranks (range, 5-4775) indicate worse outcomes. The mean summed ranks were compared by treatment group by a global statistical test (GST). (NCT00449865)
Timeframe: Change from baseline to 5 YEARS
Intervention | summed-ranks (Mean) |
---|---|
Placebo | 2360 |
Creatine | 2414 |
The McMaster Gross Motor Function is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. One of the links in this report is to the the GMFM scale and how it is scored. A link to the instrument is included. (NCT00432744)
Timeframe: Taken at 6 and 12 Months
Intervention | units on a scale (Median) |
---|---|
Placebo First | -0.002 |
CoenzymeQ10 Frist | -0.12 |
This is a multivariate analysis of the first two outcomes: Period 2 minus Period 1 GMFM88 and Peds Quality of Life, analyzed as follows: First, to be in the analysis, subjects must contribute at least one of these endpoints. Second, if the subject became totally disabled during period 1, the difference was defined as + infinity, (highest possible evidence favoring period 2), and if the subject became totally disabled in period 2, the subject was scored as - infinity (highest possible evidence favoring period 1). Period 2 minus period 1 differences were ranked form low to high with missing values scores at the mid-rank. The Hotelling T-square was computed on these ranks and the P-value was obtained from 100,000 rerandomizations as the fraction of rerandomizations with T-sq at least as large as that observed. (NCT00432744)
Timeframe: end of 12 month minus end of 6 month difference.
Intervention | participants (Number) |
---|---|
Placebo First | 7 |
CoenzymeQ10 Frist | 8 |
"The Pediatric Quality of Life Scale is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. Goggle pedsQL and Mapi to browse the copyrighted manual. A link to the instrument is included." (NCT00432744)
Timeframe: At 6 and 12 Months
Intervention | units on a scale (Median) |
---|---|
Placebo First | -1.1 |
CoenzymeQ10 Frist | -11.9 |
Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 1 |
Isradipine CR 5mg/Day | 0 |
Isradipine CR 10mg/Day | 2 |
Isradipine CR 20mg/Day | 3 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 3 |
Isradipine CR 5mg/Day | 2 |
Isradipine CR 10mg/Day | 3 |
Isradipine CR 20mg/Day | 4 |
Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 2 |
Isradipine CR 5mg/Day | 3 |
Isradipine CR 10mg/Day | 1 |
Isradipine CR 20mg/Day | 1 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 2 |
Isradipine CR 5mg/Day | 1 |
Isradipine CR 10mg/Day | 2 |
Isradipine CR 20mg/Day | 1 |
Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 7 |
Isradipine CR 5mg/Day | 5 |
Isradipine CR 10mg/Day | 6 |
Isradipine CR 20mg/Day | 6 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 3 |
Isradipine CR 5mg/Day | 1 |
Isradipine CR 10mg/Day | 1 |
Isradipine CR 20mg/Day | 1 |
General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 2 |
Isradipine CR 5mg/Day | 1 |
Isradipine CR 10mg/Day | 3 |
Isradipine CR 20mg/Day | 3 |
Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 3 |
Isradipine CR 5mg/Day | 3 |
Isradipine CR 10mg/Day | 6 |
Isradipine CR 20mg/Day | 4 |
Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 1 |
Isradipine CR 5mg/Day | 1 |
Isradipine CR 10mg/Day | 2 |
Isradipine CR 20mg/Day | 2 |
Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 2 |
Isradipine CR 5mg/Day | 3 |
Isradipine CR 10mg/Day | 1 |
Isradipine CR 20mg/Day | 1 |
Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 2 |
Isradipine CR 5mg/Day | 4 |
Isradipine CR 10mg/Day | 7 |
Isradipine CR 20mg/Day | 4 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 3 |
Isradipine CR 5mg/Day | 2 |
Isradipine CR 10mg/Day | 1 |
Isradipine CR 20mg/Day | 2 |
General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 1 |
Isradipine CR 5mg/Day | 4 |
Isradipine CR 10mg/Day | 10 |
Isradipine CR 20mg/Day | 16 |
Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 3 |
Isradipine CR 5mg/Day | 2 |
Isradipine CR 10mg/Day | 1 |
Isradipine CR 20mg/Day | 0 |
Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 2 |
Isradipine CR 5mg/Day | 3 |
Isradipine CR 10mg/Day | 2 |
Isradipine CR 20mg/Day | 0 |
Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 1 |
Isradipine CR 5mg/Day | 2 |
Isradipine CR 10mg/Day | 5 |
Isradipine CR 20mg/Day | 0 |
The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 2.60 |
Isradipine CR 5mg/Day | 3.20 |
Isradipine CR 10mg/Day | 2.09 |
Isradipine CR 20mg/Day | 1.86 |
The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | -0.52 |
Isradipine CR 5mg/Day | 1.99 |
Isradipine CR 10mg/Day | 0.11 |
Isradipine CR 20mg/Day | 1.50 |
The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 0.30 |
Isradipine CR 5mg/Day | 0.76 |
Isradipine CR 10mg/Day | 0.30 |
Isradipine CR 20mg/Day | 0.03 |
The Modified Hoehn & Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn & Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 0.27 |
Isradipine CR 5mg/Day | 0.22 |
Isradipine CR 10mg/Day | 0.12 |
Isradipine CR 20mg/Day | 0.11 |
The Schwab & England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab & England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability). (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | -5.04 |
Isradipine CR 5mg/Day | -5.56 |
Isradipine CR 10mg/Day | -3.69 |
Isradipine CR 20mg/Day | -3.76 |
The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 0.58 |
Isradipine CR 5mg/Day | 0.06 |
Isradipine CR 10mg/Day | 0.11 |
Isradipine CR 20mg/Day | 0.36 |
The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 4.32 |
Isradipine CR 5mg/Day | 3.49 |
Isradipine CR 10mg/Day | 3.91 |
Isradipine CR 20mg/Day | 3.69 |
The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | 1.28 |
Isradipine CR 5mg/Day | 3.47 |
Isradipine CR 10mg/Day | 3.00 |
Isradipine CR 20mg/Day | 3.35 |
Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | Scores on a scale (Least Squares Mean) |
---|---|
Placebo | 7.40 |
Isradipine CR 5mg/Day | 7.44 |
Isradipine CR 10mg/Day | 6.30 |
Isradipine CR 15-20mg/Day | 5.40 |
Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | participants (Number) |
---|---|
Placebo | 25 |
Isradipine CR 5mg/Day | 19 |
Isradipine CR 10mg/Day | 19 |
Isradipine CR 20mg/Day | 9 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | mm Hg (Least Squares Mean) |
---|---|
Placebo | -0.38 |
Isradipine CR 5mg/Day | -4.20 |
Isradipine CR 10mg/Day | -5.14 |
Isradipine CR 20mg/Day | -4.34 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | mm Hg (Least Squares Mean) |
---|---|
Placebo | 0.09 |
Isradipine CR 5mg/Day | -2.79 |
Isradipine CR 10mg/Day | -4.54 |
Isradipine CR 20mg/Day | -3.63 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | beats per minute (Least Squares Mean) |
---|---|
Placebo | -0.08 |
Isradipine CR 5mg/Day | -2.98 |
Isradipine CR 10mg/Day | -2.29 |
Isradipine CR 20mg/Day | -1.21 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | beats per minute (Least Squares Mean) |
---|---|
Placebo | -0.42 |
Isradipine CR 5mg/Day | -0.71 |
Isradipine CR 10mg/Day | -0.52 |
Isradipine CR 20mg/Day | 0.18 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | mm Hg (Least Squares Mean) |
---|---|
Placebo | -4.77 |
Isradipine CR 5mg/Day | -9.85 |
Isradipine CR 10mg/Day | -7.75 |
Isradipine CR 20mg/Day | -6.30 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
Intervention | mm Hg (Least Squares Mean) |
---|---|
Placebo | -2.45 |
Isradipine CR 5mg/Day | -8.59 |
Isradipine CR 10mg/Day | -6.45 |
Isradipine CR 20mg/Day | -7.01 |
11 reviews available for creatine and Idiopathic Parkinson Disease
Article | Year |
---|---|
The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials.
Topics: Activities of Daily Living; Creatine; Humans; Parkinson Disease; Randomized Controlled Trials as Top | 2017 |
Creatine for Parkinson's disease.
Topics: Activities of Daily Living; Creatine; Humans; Neuroprotective Agents; Parkinson Disease; Quality of | 2014 |
Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?
Topics: Aspartic Acid; Biomarkers; Brain; Choline; Creatine; Humans; Magnetic Resonance Spectroscopy; Molecu | 2014 |
Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Creatine; Humans; Neuroprotective Agents; Parkinson Disease; Randomiz | 2017 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutri | 2009 |
Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition.
Topics: Anti-Inflammatory Agents; Cholesterol; Creatine; Diet Therapy; Fatty Acids, Omega-3; Humans; Hydroxy | 2010 |
Bioenergetic approaches for neuroprotection in Parkinson's disease.
Topics: Acetylcarnitine; Coenzymes; Creatine; Energy Metabolism; Free Radicals; Ginkgo biloba; Humans; Mitoc | 2003 |
Mitochondria, oxidative damage, and inflammation in Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Coenzymes; Creatine; Disease Models, Animal; Free Radicals; Human | 2003 |
Methylation demand: a key determinant of homocysteine metabolism.
Topics: Animals; Creatine; Guanidinoacetate N-Methyltransferase; Homocysteine; Humans; Levodopa; Methylation | 2004 |
Clinical trials of neuroprotection for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Dopamine Agonists; Double-Blind Method; Hu | 2004 |
[Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy].
Topics: Aspartic Acid; Autonomic Nervous System Diseases; Basal Ganglia Diseases; Brain; Choline; Creatine; | 1997 |
14 trials available for creatine and Idiopathic Parkinson Disease
Article | Year |
---|---|
Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.
Topics: Age Factors; Antiparkinson Agents; Creatine; Disease Progression; Dopamine Agents; Double-Blind Meth | 2017 |
Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain-Derived Neurotrophic Factor; Cannabidiol; Creatine; Do | 2014 |
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
Topics: Aged; Antiparkinson Agents; Creatine; Disease Progression; Double-Blind Method; Drug Therapy, Combin | 2015 |
The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease.
Topics: Aged; Cognition; Cognitive Dysfunction; Creatine; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Creatine; Double-Blind Method; Female; Humans; Male; Middle Aged; Pa | 2015 |
Long-term creatine supplementation is safe in aged patients with Parkinson disease.
Topics: Creatine; Dietary Supplements; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; | 2008 |
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Creatine; Disability Evaluation; Dise | 2009 |
Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
Topics: Aged; Antipsychotic Agents; Canada; Creatine; Double-Blind Method; Evidence-Based Medicine; Female; | 2012 |
MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms.
Topics: Aged; Aspartic Acid; Biomarkers; Choline; Corpus Striatum; Creatine; Humans; Magnetic Resonance Spec | 2004 |
Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker.
Topics: Aspartic Acid; Brain Stem; Case-Control Studies; Cerebral Cortex; Creatine; Diagnosis, Differential; | 2004 |
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
Topics: Aged; Anti-Bacterial Agents; Creatine; Disabled Persons; Double-Blind Method; Female; Humans; Male; | 2006 |
Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.
Topics: Administration, Oral; Brain; Creatine; Dietary Supplements; Double-Blind Method; Female; Humans; Mal | 2006 |
1H-MRS experiences after bilateral DBS of the STN in Parkinson's disease.
Topics: Aged; Aspartic Acid; Choline; Creatine; Deep Brain Stimulation; Female; Humans; Magnetic Resonance S | 2008 |
Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.
Topics: Aged; Aspartic Acid; Corpus Striatum; Creatine; Globus Pallidus; Humans; Magnetic Resonance Spectros | 1997 |
54 other studies available for creatine and Idiopathic Parkinson Disease
Article | Year |
---|---|
Magnetic resonance spectroscopy shows associations between neurometabolite levels and perivascular space volume in Parkinson's disease: a pilot and feasibility study.
Topics: Aspartic Acid; Brain; Creatine; Feasibility Studies; Humans; Inflammation; Magnetic Resonance Imagin | 2022 |
Identification of metabolic correlates of mild cognitive impairment in Parkinson's disease using magnetic resonance spectroscopic imaging and machine learning.
Topics: Cognitive Dysfunction; Creatine; Humans; Inositol; Machine Learning; Magnetic Resonance Imaging; Mag | 2022 |
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Curcumin; Disease Models, Animal; G | 2022 |
Primary motor area-related injury of anterior central gyrus in Parkinson's disease with dyskinesia: A study based on MRS and Q-space.
Topics: Aspartic Acid; Brain; Choline; Creatine; Dyskinesias; Humans; Magnetic Resonance Imaging; Magnetic R | 2023 |
GABAergic changes in the thalamocortical circuit in Parkinson's disease.
Topics: Aged; Creatine; Dopamine Agents; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectro | 2020 |
Frontal lobe metabolic alterations characterizing Parkinson's disease cognitive impairment.
Topics: Aspartic Acid; Brain; Cognitive Dysfunction; Creatine; Frontal Lobe; Gray Matter; Humans; Magnetic R | 2021 |
Caffeine, creatine, GRIN2A and Parkinson's disease progression.
Topics: Aged; Caffeine; Creatine; Disease Progression; Female; Gene-Environment Interaction; Genetic Predisp | 2017 |
Thalamic neurometabolic alterations in tremulous Parkinson's disease: A preliminary proton MR spectroscopy study.
Topics: Aged; Aspartic Acid; Choline; Creatine; Discriminant Analysis; Dopamine Plasma Membrane Transport Pr | 2017 |
Reduced occipital GABA in Parkinson disease with visual hallucinations.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Creatine; Female; gamma-Aminobutyric Acid; Gray Matter | 2018 |
Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease.
Topics: Adult; Aged; Choline; Creatine; Dipeptides; Female; Humans; Magnetic Resonance Spectroscopy; Male; M | 2014 |
Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Creatine; Dopamine; Humans; Magnetic Resonance I | 2014 |
Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
Topics: Antiparkinson Agents; Aspartic Acid; Case-Control Studies; Choline; Creatine; Dopamine Agonists; Fem | 2015 |
Bayesian multivariate augmented Beta rectangular regression models for patient-reported outcomes and survival data.
Topics: Bayes Theorem; Creatine; Humans; Longitudinal Studies; Markov Chains; Models, Statistical; Monte Car | 2017 |
MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?
Topics: Aspartic Acid; Creatine; Female; Humans; Male; Parkinson Disease; Proton Magnetic Resonance Spectros | 2015 |
Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study.
Topics: Aged; Aspartic Acid; Biomarkers; Creatine; Female; Humans; Longitudinal Studies; Male; Middle Aged; | 2015 |
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Bayes Theorem; Case-Control Studies; Choline; Cognitive Dysf | 2016 |
Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease.
Topics: Aged; Aspartic Acid; Creatine; Female; Globus Pallidus; Humans; Magnetic Resonance Spectroscopy; Mal | 2016 |
Communicating with participants during the conduct of multi-center clinical trials.
Topics: Canada; Clinical Trials as Topic; Communication; Creatine; Double-Blind Method; Humans; Information | 2016 |
Two hundred steps.
Topics: alpha-Synuclein; Creatine; Deep Brain Stimulation; Disease Progression; Dopamine; Fetal Tissue Trans | 2016 |
Intact presupplementary motor area function in early, untreated Parkinson's disease.
Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Creatine; Female; Humans; Magnetic Resonance Spe | 2008 |
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Case-Control Studie | 2008 |
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis | 2009 |
Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease.
Topics: Animals; Clinical Trials, Phase III as Topic; Creatine; Heat-Shock Proteins; Histocompatibility Anti | 2009 |
Slowing the decline.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Humans; Indans; Parkinson Disease; Selegil | 2010 |
Correlation of findings in advanced MRI techniques with global severity scales in patients with Parkinson disease.
Topics: Aged; Brain; Choline; Corpus Striatum; Creatine; Diffusion Tensor Imaging; Dipeptides; Female; Gluta | 2011 |
Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease.
Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Creatine; Female; Humans; Imaging, Three-Dimensi | 2011 |
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure.
Topics: Adenosine Diphosphate; Adult; Age of Onset; Aged; Algorithms; Aspartic Acid; Brain Chemistry; Cholin | 2012 |
Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease.
Topics: Aged; Aspartic Acid; Case-Control Studies; Cognition Disorders; Creatine; Female; Gyrus Cinguli; Hum | 2012 |
Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial.
Topics: Bayes Theorem; Creatine; Humans; Longitudinal Studies; Parkinson Disease | 2016 |
Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients.
Topics: Aged; Aspartic Acid; Basal Ganglia; Case-Control Studies; Choline; Creatine; Female; Humans; Magneti | 2002 |
Why Rome trembles: "E avanti a lui tremava tutta Roma!" (Tosca, Act II).
Topics: Aspartic Acid; Cerebellum; Choline; Creatine; Essential Tremor; Humans; Magnetic Resonance Spectrosc | 2003 |
Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy.
Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Female; Humans; Magnetic Resonance Spectroscopy; Mal | 2003 |
Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia.
Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Cognition; Creatine; Female; Gyrus Cinguli; Huma | 2004 |
Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior.
Topics: Aged; Aspartic Acid; Brain Stem; Case-Control Studies; Choline; Creatine; Female; Humans; Inositol; | 2006 |
Certain drugs might slow progression of Parkinson's disease.
Topics: Brain; Creatine; Dopamine; Humans; Minocycline; Parkinson Disease | 2006 |
Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
Topics: Antiparkinson Agents; Aspartic Acid; Corpus Striatum; Creatine; gamma-Aminobutyric Acid; Glutamic Ac | 2007 |
Clinical research. Testing a novel strategy against Parkinson's disease.
Topics: Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Creatine; Dietary Supplements; Humans; | 2007 |
NIH announces phase III clinical trial of creatine for Parkinson's disease.
Topics: Clinical Trials, Phase III as Topic; Creatine; Dietary Supplements; Humans; National Institutes of H | 2007 |
Amantadine-dyazide interaction.
Topics: Amantadine; Ataxia; Creatine; Diuresis; Drug Combinations; Drug Synergism; Edema; Humans; Hydrochlor | 1983 |
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Basal Ganglia; Brain Diseases; Choline; Creatine; Diagnosis, Di | 1995 |
Proton MR spectroscopy of the brain in 14 patients with Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Creatine; Dementia; Energy Metabolism | 1995 |
MRS to differentiate multiple system atrophy from idiopathic Parkinson's disease.
Topics: Adult; Aged; Aspartic Acid; Basal Ganglia; Central Nervous System Diseases; Creatine; Humans; Magnet | 1993 |
Proton magnetic resonance spectroscopy with dementia.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatine; Dementia; Female; Humans | 1993 |
Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.
Topics: Aged; Apomorphine; Aspartic Acid; Basal Ganglia; Choline; Creatine; Glutamic Acid; Humans; Magnetic | 1997 |
Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Antiparkinson Agents; Aspartic Acid; Choline; Creatine; Dopamine Agents; Humans; Levodo | 1997 |
Proton MR spectroscopic imaging of the striatum in Parkinson's disease.
Topics: Adult; Aged; Aspartic Acid; Biomarkers; Choline; Corpus Striatum; Creatine; Female; Humans; Magnetic | 1997 |
Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Brain Diseases; Choline; Creatine; Female; Humans; Ma | 1997 |
Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Brain Chemistry; Choline; Creatine; Female; Globus Pallidus; Humans; Mag | 1998 |
A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.
Topics: Aged; Aspartic Acid; Cerebral Cortex; Choline; Corpus Striatum; Creatine; Female; Glutamic Acid; Glu | 1999 |
Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Basal Ganglia; Choline; Creatine; Glutamic Acid; Glutamine; Humans; Magn | 2000 |
Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients.
Topics: Aged; Aspartic Acid; Basal Ganglia; Brain Chemistry; Choline; Creatine; Female; Humans; Inositol; Ma | 2001 |
Muscle metabolism during exercise in patients with Parkinson's disease.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Aged; Blood Flow Velocity; Blood Glucose; Carbon | 1974 |
Separation and determination of urinary homovanillic acid and iso-homovanillic acid by gas-liquid chromatography and electron capture detection.
Topics: Adolescent; Adult; Child; Chromatography, Gas; Creatine; Dihydroxyphenylalanine; Homovanillic Acid; | 1973 |
Some common factors in the causation of postural hypotension.
Topics: 17-Ketosteroids; Aged; Arrhythmias, Cardiac; Asthenia; Blood Pressure; Blood Volume; Chlorides; Crea | 1969 |